relatlimab (BMS-986016)

The largest adequately powered signals were observed for pembrolizumab (ROR 18.34, n = 258), nivolumab (ROR 18.65, n = 256), atezolizumab (ROR 22.22, n = 132), and ipilimumab (ROR 15.11, n = 73); cemiplimab (ROR 46.89), relatlimab (ROR 44.68), and dostarlimab (ROR 33.48) produced high-magnitude estimates with smaller case counts. The DM phenotype is more consistently disproportionate than PM across classes, with mechanistic plausibility given PD-L1's role in restraining interferon-producing plasmacytoid dendritic cells. The immune-mediated myositis MedDRA term captures the most statistically robust signal, reflecting a distinct ICI-associated coding pattern in spontaneous reporting.

A personalized surgical approach to neoadjuvant ICI was feasible, with comparable recurrence rates between the patients who underwent INE and those who underwent TLND. For the patients without MPR, subsequent adjuvant therapy improved recurrence-free survival (p = 0.046). The ctDNA results correlated with the clinical outcomes, suggesting that ctDNA may complement pathologic response in guiding management.

Melanoma remains one of the most aggressive cutaneous malignancies, accounting for a disproportionate share of skin cancer-related mortality despite relatively lower incidence. Emerging data from the NADINA trial establish a compelling neoadjuvant role for the combination, while the adjuvant CheckMate 915 trial failed to demonstrate recurrence-free survival benefit over nivolumab monotherapy. Future progress will depend on biomarker-driven personalization, refined sequencing strategies, and integration of the combination within an increasingly competitive first-line landscape that now includes nivolumab plus relatlimab.

We describe the case of a man in his 60s with metastatic melanoma on encorafenib/binimetinib and nivolumab/relatlimab, with a history of immune checkpoint inhibitor (ICI)-induced acute interstitial nephritis, who presented with acute-onset nausea, vomiting and profuse watery diarrhoea. His symptoms persisted despite discontinuation of Braftovi-Mektovi (BRAF-MEK) therapy and required escalation of corticosteroid therapy and budesonide initiation. This case highlights the diagnostic challenges of differentiating ICI-mediated colitis from adverse events of targeted therapy and underscores the importance of endoscopic and histological confirmation in guiding treatment.

P2, N=225, Terminated, Iovance Biotherapeutics, Inc. | Trial completion date: Aug 2029 --> Feb 2026 | Recruiting --> Terminated | Trial primary completion date: Aug 2029 --> Feb 2026; After reviewing the available safety and efficacy data to date, Iovance concluded that the study reached the required number of events for evaluation of study endpoints.

P1/2, N=21, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Apr 2026 --> Dec 2026

Immune checkpoint receptors (LAG3, CD27) connect via PPI intermediates to Ca2+ and K+ channels, targetable by relatlimab (FDA-approved) and varlilumab (Phase 2). This work maps previously unknown links between CRC driver genes and ion channel regulation, with the ataluren-RPS21-KCNQ2 axis ready for pharmacological testing.

P3, N=360, Recruiting, Immatics US, Inc. | N=108 --> 360

P3, N=108, Recruiting, Immatics US, Inc.

P2, N=80, Active, not recruiting, Dan Zandberg | Recruiting --> Active, not recruiting

P4, N=90, Recruiting, NYU Langone Health | Not yet recruiting --> Recruiting

P3, N=360, Recruiting, Immatics US, Inc. | N=96 --> 360